Seed Therapeutics
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
411 Swedeland Rd Ste 1000, King Of Pruss...Phone Number
(646) 305-6387Website
www.seedtherapeutics.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Seed Therapeutics
SEED Therapeutics specializes in designing molecular glue degraders that utilize the full E3 ligase universe to target and eliminate disease proteins, particularly in oncology. Their innovative RITE3 platform enables the identification of optimal ligase-target pairs, allowing for a more precise approach to targeted protein degradation. The company is currently advancing its lead product, ST-01156, through Phase 1 trials for various tumors, supported by strategic partnerships with industry leaders like Lilly and Eisai. SEED Therapeutics aims to make a significant impact on patient care by developing therapies for diseases where traditional treatments have failed.Explore more
Seed Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seed Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Seed Therapeutics has new funding data
Product Launch: Get notified when Seed Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Seed Therapeutics is spiking on competitors!
Earning: See what the market has to say on Seed Therapeutics recently announced quarterly report
Check if Seed Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Seed Therapeutics had a recent Job posting/layoffs
Seed Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Seed Therapeutics
Recommended Actions
Find VP level buyers at Seed Therapeutics
Find 3 more new buyers
Compare Similar Companies to Seed Therapeutics
Compare insights from companies similar to Seed Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Seed Therapeutics
$5.3M
11-50
Private
-
-
William DesmaraisChief Financial Officer & Chief Business Officer
Company Profile Activity
Activity Insights
Seed Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Seed Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Seed Therapeutics.
Seed Therapeutics Tech Stack
A closer look at the technologies used by Seed Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Board of Directors
Executive Move
Seed Therapeutics News & Media
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing Sarcoma, Hepatocellular Carcinoma, KRAS-Mutant Cancers, Neuroblastoma, and Other RBM39-Dependent Tumors Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing Sarcoma, Hepatocellular Carcinoma, KRAS-Mutant Cancers, Neuroblastoma, and Other RBM39-Dependent TumorsSEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
KING OF PRUSSIA, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, today announced that it will present a poster on ST-01156, its orally administered, selective RBM39 molecular glue degrader currently in a first-in-human Phase 1 study, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. The poster will descriSEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156
Phase 1 Dose Escalation Underway at Six Leading U.S. Oncology Centers; MYC Overexpression and CDKN2A/B Deletion Identified as Potential Patient-Selection Biomarkers — Data Presented at AACR Annual Meeting 2026 Phase 1 Dose Escalation Underway at Six Leading U.S. Oncology Centers; MYC Overexpression and CDKN2A/B Deletion Identified as Potential Patient-Selection Biomarkers — Data Presented at AACR Annual Meeting 2026SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Seed Therapeutics
Sign Up For FreeTo access detailed company insights
SEED Therapeutics specializes in designing molecular glue degraders that utilize the full E3 ligase universe to target and eliminate disease proteins, particularly in oncology. Their innovative RITE3 platform enables the identification of optimal ligase-target pairs, allowing for a more precise approach to targeted protein degradation. The company... Read More
